Hutchmed Closes GSK License Deal for KRAS-EGFR Cancer Therapy
MT Newswires Live
Oct 21
Hutchmed (HCM) closed a licensing agreement granting a GSK (GSK) unit worldwide development and commercialization rights to its experimental cancer drug HMPL-A830, excluding mainland China, Hong Kong, Macau and Taiwan, the company said late Tuesday.
Under the deal, Hutchmed expects to receive an upfront payment of $110 million, with potential milestone payments of up to about $1.19 billion and tiered royalties on annual net sales.
Hutchmed will lead global phase I development, while GSK will oversee subsequent clinical development and commercialization in its licensed territories, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.